We have demonstrated the potential for radiosensitization of TNBC models utilizing all 3 of the clinically approved CDK4/6 inhibitors, but in future studies, we will evaluate whether this strategy is effective in other histopathological classifications or subtypes of breast cancer, such as inflammatory breast cancer, lobular breast cancer, and HER2-enriched breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.